Back to Sites

University of Colorado Denver NICHD CRS

Site Number

5052

Address

University of Colorado Denver
Department of Pediatrics
13123 E. 16th Ave. B055
Aurora, CO 80045
United States of America

IMPAACT Members at this Site

Katherine Bell CAB Member

Jennifer Dunn Co-Investigator

Gretchen Heinrichs Co-Investigator

Jody Maes Co-Investigator

Elizabeth (Betsy) McFarland Co-Investigator

Daniel Reirden Co-Investigator

Adriana Weinberg Co-Investigator

Carrie Chambers CRS Coordinator

Myron Levin CRS Leader

Tara Kennedy Investigator

Patricia Michalek Investigator

Suzanne Paul Investigator

Paul Harding Laboratory Manager/Supervisor

Jennifer Englund Regulatory Coordinator

Eva Ernevad Regulatory Coordinator

Kerry Hahn Research Assistant

Tori Rutherford Research Assistant

Jenna Wallace Research Assistant

Erica Myruski Research Nurse

Amy Witte Research Nurse

Jessie Robinson Senior Manager

Erin Austin Study Coordinator

Emily Barr Study Coordinator

Shane Curran-Hayes Study Coordinator

Christine Kwon Study Coordinator

Carol Salbenblatt Study Coordinator

Studies at this Site

P1112: Monoclonal Antibody PK Study

DAIDS Number

11903

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

P1114: Safety and Immunogenicity of an RSV Vaccine cps2

DAIDS Number

11948

Research Area

Complications & Comorbidities

Study Status

Concluded

P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study

DAIDS Number

11954

Research Area

Cure and Immunotherapy

Study Status

Enrolling

IMPAACT 2000: A Phase I Study of the Safety and Immunogenicity of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID delta M2-2 in RSV-Seronegative Infants and Children

DAIDS Number

12016

Research Area

Complications & Comorbidities

Study Status

Concluded

IMPAACT 2002: Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression among Youth Living with HIV in the United States

DAIDS Number

12051

Research Area

Brain and Mental Health

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2007: Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection

DAIDS Number

20734

Research Area

Treatment

Study Status

Concluded

IMPAACT 2011: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID delta M2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

30072

Research Area

Complications & Comorbidities

Study Status

Concluded

IMPAACT 2012: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID cp delta M2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

30073

Research Area

Complications & Comorbidities

Study Status

Concluded

IMPAACT 2013: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, D46/NS2/N/delta M2-2-HindIII, Lot RSV#011B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

30074

Research Area

Complications & Comorbidities

Study Status

Concluded

IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents

DAIDS Number

34150

Research Area

Treatment

Study Status

Concluded